Department of Public Health and Community Medicine, Director of Tufts University, Boston, MA, United States of America.
Affiliate of Cochrane US, Tufts University School of Medicine, Boston, MA, United States of America.
PLoS One. 2024 Mar 18;19(3):e0294475. doi: 10.1371/journal.pone.0294475. eCollection 2024.
Despite conflicting findings in the current literature regarding the correlation between contraceptives and maternal health consequences, statistical analyses indicate that family planning may decrease the occurrence of such outcomes. Consequently, it is crucial to assess the capability of family planning to mitigate adverse maternal health outcomes.
This review investigates the effects of modern contraceptive use on maternal health.
This systematic review is registered on Prospero (CRD42022332783). We searched numerous databases with an upper date limit of February 2022 and no geographical boundaries.
We included observational studies, including cross-sectional, cohort, case-control studies, and non-RCT with a comparison group. We excluded systematic reviews, scoping reviews, narrative reviews, and meta-analyses from the body of this review.
The review included nineteen studies, with five studies reporting a reduction in maternal mortality linked to increased access to family planning resources and contraceptive use. Another three studies examined the impact of contraception on the risk of preeclampsia and our analysis found that preeclampsia risk was lower by approximately 6% among contraceptive users (95% CI 0.82-1.13) compared to non-users. Two studies assessed the effect of hormonal contraceptives on postpartum glucose tolerance and found that low-androgen contraception was associated with a reduced risk of gestational diabetes (OR 0.84, 95% CI 0.58-1.22), while DMPA injection was possibly linked to a higher risk of falling glucose status postpartum (OR 1.42, 95% CI 0.85-2.36). Two studies evaluated high-risk pregnancies and births in contraceptive users versus non-users, with the risk ratio being 30% lower among contraceptive users of any form (95% CI 0.61, 0.80). None of these results were statistically significant except the latter. In terms of adverse maternal health outcomes, certain contraceptives were found to be associated with ectopic pregnancy and pregnancy-related venous thromboembolism through additional analysis.
尽管当前文献中关于避孕药与产妇健康后果之间的相关性存在矛盾的发现,但统计分析表明,计划生育可能会减少此类结果的发生。因此,评估计划生育减轻不良产妇健康结果的能力至关重要。
本综述调查了现代避孕药使用对产妇健康的影响。
本系统评价已在 Prospero(CRD42022332783)上注册。我们搜索了多个数据库,截止日期为 2022 年 2 月,没有地理边界。
我们纳入了观察性研究,包括横断面、队列、病例对照研究和非随机对照试验,且有对照组。我们从综述中排除了系统评价、范围综述、叙述性综述和荟萃分析。
该综述纳入了 19 项研究,其中 5 项研究报告称,增加计划生育资源和避孕药具的可及性可降低产妇死亡率。另外 3 项研究评估了避孕对先兆子痫风险的影响,我们的分析发现,与非使用者相比,避孕药使用者的先兆子痫风险降低了约 6%(95%CI 0.82-1.13)。两项研究评估了激素避孕药对产后葡萄糖耐量的影响,发现低雄激素避孕药与降低妊娠期糖尿病的风险相关(OR 0.84,95%CI 0.58-1.22),而 DMPA 注射可能与产后血糖状态下降的风险升高相关(OR 1.42,95%CI 0.85-2.36)。两项研究评估了避孕药使用者与非使用者的高危妊娠和分娩,任何形式的避孕药使用者的风险比降低了 30%(95%CI 0.61,0.80)。除了最后一个结果外,这些结果都没有统计学意义。在不良产妇健康结果方面,通过额外分析发现,某些避孕药与异位妊娠和妊娠相关静脉血栓栓塞有关。